Crohn's Disease

Etrasimod helped patients with moderate-to-severe ulcerative colitis achieve clinical and endoscopic improvements, according to research published in Gastroenterology.

Despite progress in treatment for inflammatory bowel disease, patients and providers reported differing expectations as to remission and other aspects of disease control in a recent global survey, as presented in a poster during the 2020 Congress of the European Crohn’s and Colitis Organisation.

Jami Kinnucan, MD, assistant professor at the University of Michigan, spoke with Healio about cannabis use among patients with ulcerative colitis and Crohn’s disease, the impact of diet on IBD management and the overall role of complementary therapy in the GI field, specifically for patients with IBD.

In this exclusive video from the GUILD Conference 2020, Edward V. Loftus Jr., MD, professor of medicine in the division of gastroenterology and hepatology at the Mayo Clinic in Rochester, Minnesota, discusses his presentation on some of the important updates in Crohn’s disease in 2019.

One of the top stories in gastroenterology last week was a guest commentary that provided an inside look at abdominal pain in patients with irritable bowel syndrome.

Feza Remzi, MD, FACS, FTSS(Hon), director of the Inflammatory Bowel Disease Center and professor of surgery at New York University Robert Grossman School of Medicine and NYU Langone Health, spoke with Healio about the importance of collaboration between surgeons and gastroenterologists, the role of ultrasonography for patients with Crohn’s disease in the United States and surgery’s place in the continuum of care.

MAUI, Hawaii — Certain inflammatory bowel disease therapies may further increase malignancies in patients with Crohn’s disease or ulcerative colitis, according to an expert at the GUILD Conference 2020.

MAUI, Hawaii – Nearly a third of patients with Crohn’s disease will develop an abdominal abscess from a fistula during disease management. A presenter at the GUILD Conference reported that a surgical approach often produces better outcomes than medical therapy alone.

MAUI, Hawaii — JAK inhibitors offer quick results, improved quality of life and lower serious adverse events for patients with inflammatory bowel disease, according to an expert at the GUILD Conference 2020.

MAUI, Hawaii — In this exclusive video from GUILD Conference 2020, Miguel Regueiro, MD, discusses his presentation on the management of intra-abdominal abscesses in patients with Crohn’s disease.